A Phase Ib Clinical Trial of TQB3454 Tablets in Patients With Blood Tumors
Latest Information Update: 29 Jan 2024
At a glance
- Drugs TQB 3454 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 29 Jan 2024 New trial record